MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
0.3551
+0.0266
+8.10%
Opening 15:23 04/01 EDT
OPEN
0.3368
PREV CLOSE
0.3285
HIGH
0.3783
LOW
0.3327
VOLUME
8.40M
TURNOVER
--
52 WEEK HIGH
3.870
52 WEEK LOW
0.3200
MARKET CAP
82.19M
P/E (TTM)
-0.4763
1D
5D
1M
3M
1Y
5Y
1D
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
PR Newswire · 10h ago
Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit
Barchart · 10h ago
Weekly Report: what happened at GOSS last week (0323-0327)?
Weekly Report · 2d ago
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
PR Newswire · 03/25 13:00
Gossamer Bio downgraded by Cantor on unclear regulatory path for seralutinib
Seeking Alpha · 03/23 19:20
This Box Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Benzinga · 03/23 15:38
Morning Movers: Apogee surges following APEX clinical trial readout
TipRanks · 03/23 13:11
Weekly Report: what happened at GOSS last week (0316-0320)?
Weekly Report · 03/23 10:24
More
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.